Related Experiment Video
Updated: Aug 4, 2025
Author Spotlight: Exploring Strategies for Successful Immune Response Against Tumors
Published on: August 16, 2024
Worth a Pound of Cure? Emerging Strategies and Challenges in Cancer Immunoprevention
Saurav D Haldar1, Eduardo Vilar2, Anirban Maitra3
1Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
Abstract:
Cancer immunoprevention applies immunologic approaches such as vaccines to prevent, rather than to treat or cure, cancer. Despite limited success in the treatment of advanced disease, the development of cancer vaccines to intercept premalignant states is a promising area of current research. These efforts are supported by the rationale that vaccination in the premalignant setting is less susceptible to mechanisms of immune evasion compared with established cancer. Prophylactic vaccines have already been developed for a minority of cancers mediated by oncogenic viruses (e.g., hepatitis B and human papillomavirus). Extending the use of preventive vaccines to non-virally driven malignancies remains an unmet need to address the rising global burden of cancer. This review provides a broad overview of clinical trials in cancer immunoprevention with an emphasis on emerging vaccine targets and delivery platforms, translational challenges, and future directions.
Insights
Cancer immunoprevention uses vaccines to prevent cancer before it starts, offering a promising strategy against premalignant states. This approach is crucial for tackling non-virally driven cancers and the global cancer burden.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Cancer immunoprevention focuses on preventing cancer using immunologic strategies, particularly vaccines, targeting premalignant stages.
- Vaccination in the premalignant setting may overcome immune evasion mechanisms seen in established cancers.
- Existing prophylactic vaccines target virus-mediated cancers (e.g., Hepatitis B, Human Papillomavirus).
Approach:
- This review examines clinical trials in cancer immunoprevention.
- Emphasis is placed on novel vaccine targets and delivery systems.
- The review also discusses translational challenges and future research directions.
Key Points:
- Developing preventive vaccines for non-virally driven malignancies is a critical unmet need.
- Immunoprevention offers a proactive approach to combat the increasing global cancer burden.
- Early-stage intervention via vaccination is less prone to cancer immune evasion.
Conclusions:
- Cancer immunoprevention is a rapidly evolving field with significant potential.
- Further research into vaccine targets, delivery platforms, and overcoming translational hurdles is essential.
- Expanding preventive vaccine strategies to non-viral cancers is a key future direction.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:59Cancer Prevention
Some...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...